上海復旦張江生物醫藥股份有限公司

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code:1349)

INSIDE INFORMATION
ANNOUNCEMENT OF PRELIMINARY ANNUAL RESULTS FOR THE YEAR 2022

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, of the Laws of Hong Kong).

In accordance with the relevant laws, regulations and regulatory requirements in Mainland China, the Company should disclose the key financial data for the year ended 31 December 2022 (the "**Reporting Period**") in accordance with the China Accounting Standards for Business Enterprises on the website of the Shanghai Stock Exchange. The data set out in this announcement are preliminarily prepared by the management of the Company, which has not been audited by the Company's auditors. The final audited results will be disclosed in the final result of the Group for the year ended 31 December 2022 and 2022 annual report. Prospective investors and shareholders of the Company are advised to pay attention to the potential investment risks.

I. KEY FINANCIAL DATA AND INDICATORS OF THE GROUP FOR THE YEAR ENDED 31 DECEMBER 2022:

Unit:RMB

Item	Reporting Period	Corresponding period of last year	Change (%)
Revenue	1,031,159,838	1,140,313,088	-9.57
Operating profit	133,271,437	217,377,702	-38.69
Total Profit	132,293,548	215,920,869	-38.73
Net profit attributable to shareholders of the listed company	137,997,098	213,295,758	-35.30
Net profit deducting non-recurring profit or loss attributable to shareholders of the listed company	112,051,414	173,169,675	-35.29
Basic earnings per share(RMB per share)	0.13	0.21	-38.10
Weighted average rate of return on net assets (%)	6.21	10.42	Decreased by 4.21 percentage point

Item	As at the end of Reporting Period	As at the beginning of Reporting Period	Change (%)
Total assets	2,976,007,272	2,781,172,268	7.01
Net assets attributable to shareholders of the listed company	2,257,102,217	2,192,945,932	2.93
Share capital	102,900,000	104,300,000	-1.34
Net assets per share attributable to shareholders of the listed Company	2.19	2.10	4.29

Notes:

1. The data as at the beginning of the Reporting Period are the same as the audited amounts as at the end of the previous year;
2. The above financial data and indicators were extracted from data of the unaudited consolidated financial statements.

II . INFORMATION ON THE OPERATION RESULTS AND FINANCIAL CONDITION

Operation and Financial Condition and Factors Affecting Operation Results During the Reporting Period

In 2022, the national situation of the COVID-19 epidemic (the "**Epidemic**") was severe, and in accordance with the Epidemic prevention and control policy in the PRC, multiple regions gradually implemented static management, which caused certain difficulties to the Company's normal production, operation and research and development projects. The Group actively organized production and logistics with good Epidemic precautions to minimize the impact of the Epidemic, and the production and sales of drugs gradually recovered during the third quarter of 2022. But due to the reversal of the Epidemic in multiple regions in the fourth quarter of 2022, the products transportation and the treatment of patients were restricted again, and there was delay in the supply of imported raw materials which caused the production and delivery of products could not be completed as planned. These resulted in a decrease in revenue of the year 2022 of the Company as compared to that in 2021, leading to a decrease in other relevant financial data.

Explanation for Items with over 30% Change in the Table above

During the Reporting Period, the significant decrease of the operating profit, total profit, net profit attributable to shareholders of the listed company, net profit deducting non-recurring profit or loss attributable to shareholders of the listed company and basic earnings per share was mainly due to the reversal outbreaks of the Epidemic and the Epidemic prevention and control policy had a significant impact on main business of the Company, resulting in a decline in relevant financial data such as revenue compared with the same period of last year; and due to the decrease of government grants received and investment income recognized for current period causes a significant decline in operating profit compared with the same period of last year, resulting a drop in other relevant financial data.

By order of the Board
Wang Hai Bo
Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)
Mr. Su Yong (Executive Director)
Mr. Zhao Da Jun (Executive Director)
Mr. Shen Bo (Non-executive Director)
Ms. Yu Xiao Yang (Non-executive Director)
Mr. Zhou Zhong Hui (Independent Non-executive Director)
Mr. Lam Yiu Kin (Independent Non-executive Director)
Mr. Xu Qing (Independent Non-executive Director)
Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

27 February 2023

** For identification purpose only*